Kawsar Talaat, one of the principal investigators of the Pfizer pediatric trial and a physician at Johns Hopkins Bloomberg School of Public Health, said that while the news may be disappointing, a third dose is expected to work well to provide protection, particularly against omicron.
Pfizer to test a third dose of coronavirus vaccine in young children after two-dose regimen falls short – The Washington Post
